
Dimerix Investor Relations Material
Latest events

Investor Presentation
18 Jun, 2025

Study Update
12 Jun, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Dimerix Limited
Access all reports
Dimerix Limited is an Australian biopharmaceutical company focused on developing new therapies for rare and progressive diseases, particularly kidney and inflammatory diseases. The company’s lead candidate targets chronic kidney diseases, including focal segmental glomerulosclerosis (FSGS) and diabetic kidney disease, using a proprietary drug discovery and development platform. Dimerix applies receptor-based science to create treatments that address unmet medical needs in complex diseases with few current therapeutic options. The company is involved in clinical trials to advance its drug candidates towards regulatory approval. The company is headquartered in Melbourne, Victoria, and its shares are listed on the ASX.
Key slides for Dimerix Limited


Company Presentation
Dimerix Limited


Investor Presentation
Dimerix Limited
Latest articles
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
Ticker symbol
DXB
Country
🇦🇺 Australia